TY - JOUR
T1 - The impact in older women of ovarian FMR1 genotypes and sub-genotypes on ovarian reserve
AU - Gleicher, Norbert
AU - Weghofer, Andrea
AU - Kim, Ann
AU - Barad, David H.
N1 - Funding Information:
NG is owner of CHR, a for-profit infertility center, where this research was conducted. NG and DHB are listed as co-inventors on a number of pending, and one already awarded, U.S. patents claiming diagnostic benefits from dehydroepiandrosterone (DHEA)/androgen supplementation in women with diminished ovarian reserve (DOR). CHR recently received notice that a second U.S. DHEA patent, including the claim that DHEA/androgen supplementation reduces embryo aneuploidy in women with DOR, would be issued in the near future. NG and DHB are also co-inventors on a number of pending U.S. patent applications, claiming diagnostic relevance for the assessment of CGG triple repeats on the FMR1 gene in determining risk toward DOR and related issues. NG, AW, and DHB have in the past received research support, travel funds and speakers' honoraria from different pharma and medical device companies, none, however, in any way related to the here presented research data. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors. At the time of this submission only one U.S. user patent with any relevance to this manuscript has been awarded (November 10, 2009; #7615544). It claims benefits from supplementation with DHEA/Androgens on ovarian reserve and pregnancy rates in women with DOR. Above noted second user patent (#12/123,877) is expected within weeks from this submission, claiming expanded benefits on pregnancy chances and decreased embryo aneuploidy (and, therefore, miscarriage risk) from DHEA/androgen supplementation. Among patent applications pending in regards to the FMR1 gene, one describes ovarian genotypes and sub-genotypes used in this manuscript, and claims that they reflect different ovarian aging patterns. All patent applications filed by researchers at CHR are 50% owned by CHR and 50% by the investigators who did the research that led to the application. A full list of all patent information can be provided on request. This study was partially funded by CHR.
PY - 2012/3/16
Y1 - 2012/3/16
N2 - We recently associated ovarian FMR1genotypes and sub-genotypes with distinct ovarian aging patterns. How they impact older females is, however, unknown. We, therefore, investigated 217 consecutive first in vitro fertilization (IVF) cycles in women >40 assessing oocyte yields, stratified for better (anti-Müllerian hormone, AMH >1.05 ng/mL) or poorer (AMH≤1.05 ng/mL) functional reserve (FOR)). Mean age was 42.4±2.0 years, mean AMH 0.76±0.92 ng/mL and mean oocyte yield 5.3±5.4. Overall, and in women with better FOR, FMR1 did not affect oocyte yields. With poorer FOR (AMH≤1.05 ng/mL) women with het-norm/high, however, demonstrated higher oocyte yields (5.0±3.8) than those with het-norm/low sub-genotype 3.1±2.5; P = 0.03), confirmed after log conversion. Known associated with low FOR at young age, het-norm/high, thus, appears to preserve FOR into older age, and both het sub-genotypes appear to expand female reproductive lifespan into opposite directions.
AB - We recently associated ovarian FMR1genotypes and sub-genotypes with distinct ovarian aging patterns. How they impact older females is, however, unknown. We, therefore, investigated 217 consecutive first in vitro fertilization (IVF) cycles in women >40 assessing oocyte yields, stratified for better (anti-Müllerian hormone, AMH >1.05 ng/mL) or poorer (AMH≤1.05 ng/mL) functional reserve (FOR)). Mean age was 42.4±2.0 years, mean AMH 0.76±0.92 ng/mL and mean oocyte yield 5.3±5.4. Overall, and in women with better FOR, FMR1 did not affect oocyte yields. With poorer FOR (AMH≤1.05 ng/mL) women with het-norm/high, however, demonstrated higher oocyte yields (5.0±3.8) than those with het-norm/low sub-genotype 3.1±2.5; P = 0.03), confirmed after log conversion. Known associated with low FOR at young age, het-norm/high, thus, appears to preserve FOR into older age, and both het sub-genotypes appear to expand female reproductive lifespan into opposite directions.
UR - https://www.scopus.com/pages/publications/84858602064
U2 - 10.1371/journal.pone.0033638
DO - 10.1371/journal.pone.0033638
M3 - Article
C2 - 22438971
AN - SCOPUS:84858602064
SN - 1932-6203
VL - 7
JO - PLoS ONE
JF - PLoS ONE
IS - 3
M1 - e33638
ER -